CAC
EBS icon

Core Alternative Capital’s Emergent Biosolutions EBS Stock Holding History

Core Alternative Capital’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-133
Closed -$5K – 430
2022
Q1 		$5K Buy
+133
New +$5.87K ﹤0.01% 351

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Core Alternative Capital's EBS Position: Q2 2022 in Review

Core Alternative Capital sold out of Emergent Biosolutions (EBS) in Q2 2022, closing a stake of 133 shares — an estimated $5K sold.

Core Alternative Capital first reported a position in EBS in Q1 2022 and held it in 1 quarter. The position peaked at $5K in Q1 2022. 232 funds tracked by Wall St. Rank hold EBS as of Q2 2022.

  • Core Alternative Capital reported no remaining Emergent Biosolutions position as of Q2 2022 after selling out during the quarter.
  • Core Alternative Capital sold 133 Emergent Biosolutions shares in Q2 2022, an estimated $5K.
  • Core Alternative Capital first reported a position in Emergent Biosolutions in Q1 2022 and held it in 1 quarter.
  • Core Alternative Capital's Emergent Biosolutions position peaked at $5K in Q1 2022.
  • 232 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2022.

Based on Core Alternative Capital's 13F filing for Q2 2022, filed 1 Aug 2022.